Insider Selling: Adaptive Biotechnologies (NASDAQ:ADPT) COO Sells 19,460 Shares of Stock

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) COO Julie Rubinstein sold 19,460 shares of the company’s stock in a transaction dated Tuesday, March 10th. The shares were sold at an average price of $14.68, for a total transaction of $285,672.80. Following the transaction, the chief operating officer owned 643,471 shares in the company, valued at $9,446,154.28. This represents a 2.94% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Julie Rubinstein also recently made the following trade(s):

• On Monday, March 9th, Julie Rubinstein sold 30,941 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $14.79, for a total value of $457,617.39.
• On Tuesday, March 3rd, Julie Rubinstein sold 30,941 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $15.67, for a total transaction of $484,845.47.
• On Thursday, March 5th, Julie Rubinstein sold 30,941 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $16.00, for a total transaction of $495,056.00.

Adaptive Biotechnologies Stock Down 2.9%

ADPT traded down $0.43 during trading on Tuesday, hitting $14.52. The company’s stock had a trading volume of 1,839,163 shares, compared to its average volume of 1,587,589. Adaptive Biotechnologies Corporation has a one year low of $6.26 and a one year high of $20.76. The business’s 50 day simple moving average is $16.72 and its 200-day simple moving average is $15.88. The firm has a market cap of $2.24 billion, a PE ratio of -36.30 and a beta of 2.19.

Adaptive Biotechnologies (NASDAQ:ADPT) last released its earnings results on Thursday, February 5th. The company reported ($0.09) earnings per share for the quarter, beating the consensus estimate of ($0.19) by $0.10. Adaptive Biotechnologies had a negative return on equity of 46.68% and a negative net margin of 21.48%.The company had revenue of $71.68 million for the quarter, compared to the consensus estimate of $59.38 million. During the same period in the previous year, the business earned ($0.23) earnings per share. Adaptive Biotechnologies’s quarterly revenue was up 51.0% compared to the same quarter last year. Equities research analysts expect that Adaptive Biotechnologies Corporation will post -0.92 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms have commented on ADPT. JPMorgan Chase & Co. raised their target price on shares of Adaptive Biotechnologies from $20.00 to $21.00 and gave the stock an “overweight” rating in a research note on Friday, February 6th. Morgan Stanley assumed coverage on shares of Adaptive Biotechnologies in a research note on Monday, December 1st. They set an “equal weight” rating and a $21.00 target price on the stock. Wall Street Zen downgraded shares of Adaptive Biotechnologies from a “buy” rating to a “hold” rating in a report on Saturday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Adaptive Biotechnologies in a research note on Wednesday, January 21st. Finally, Guggenheim boosted their price objective on Adaptive Biotechnologies from $20.00 to $21.00 and gave the company a “buy” rating in a research report on Monday, January 26th. Seven research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Adaptive Biotechnologies presently has an average rating of “Moderate Buy” and a consensus target price of $18.25.

Institutional Trading of Adaptive Biotechnologies

Hedge funds have recently bought and sold shares of the stock. Caitong International Asset Management Co. Ltd bought a new position in shares of Adaptive Biotechnologies during the 4th quarter valued at about $28,000. Sound Income Strategies LLC bought a new stake in shares of Adaptive Biotechnologies in the third quarter worth about $30,000. EverSource Wealth Advisors LLC lifted its position in shares of Adaptive Biotechnologies by 197.1% in the fourth quarter. EverSource Wealth Advisors LLC now owns 2,359 shares of the company’s stock worth $38,000 after buying an additional 1,565 shares in the last quarter. Assetmark Inc. boosted its stake in Adaptive Biotechnologies by 867.9% during the fourth quarter. Assetmark Inc. now owns 3,020 shares of the company’s stock valued at $49,000 after buying an additional 2,708 shares during the last quarter. Finally, T. Rowe Price Investment Management Inc. bought a new position in Adaptive Biotechnologies during the fourth quarter valued at approximately $51,000. Hedge funds and other institutional investors own 99.17% of the company’s stock.

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.